TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8636182

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg body-weight, intravenously before tourniquet release and repeated three hours later)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tranexamic acid and Placebo
Number of subjects: 86
Study: 1450477

Group type: EXPERIMENTAL
Intervention: Cuprophane (CU) bicarbonate hemodialysis
Number of subjects: 6

Group type: COMPARATOR
Intervention: Polysulfone (PS) bicarbonate hemodialysis
Number of subjects: 6
Study: 6380565

Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study: 31622473

Group type: EXPERIMENTAL
Intervention: Coherent sequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random order sequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase-randomized scenes
Number of subjects: 0
Study: 30389894

Group type: EXPERIMENTAL
Intervention: Multivariable predictive model based on baseline covariates and follow-up data
Number of subjects: 0
Study: 26842871

Group type: EXPERIMENTAL
Intervention: Advanced multidisciplinary self‐management patient education program
Number of subjects: 566

Group type: COMPARATOR
Intervention: Standard patient education programs
Number of subjects: 566
Study: 24274030

Group type: EXPERIMENTAL
Intervention: Hydrogen-enriched solution (H2‐HD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard solution
Number of subjects: 8
Study: 23211655

Group type: EXPERIMENTAL
Intervention: Electronic case report forms (eCRF)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Paper-based case report forms (CRF)
Number of subjects: 760
Study: 20675426

Group type: EXPERIMENTAL
Intervention: 5 As (Ask, Advise, Assess, Assist, Arrange)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: 3 As (AAR model)
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Combined intervention conditions (5 As and 3 As)
Number of subjects: 2160
Study: 17414000

Group type: EXPERIMENTAL
Intervention: Intravascular cooling catheter (Coolgard, Alsius, CA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional treatment (antipyretic drugs and/or surface cooling techniques)
Number of subjects: 26
Study: 16335643

Group type: EXPERIMENTAL
Intervention: Vision screening by trained school nurses
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: Vision test sensitivity in females, older students, and North Sharqiya region
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: General vision screening of school students in Oman
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: Periodic training of nurses and supervision of screening procedures
Number of subjects: 1719
Study: 11703862

Group type: EXPERIMENTAL
Intervention: Autologous whole blood (WB)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Autologous fresh-frozen plasma and buffy coat-poor red cells (RC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No transfusion (NT)
Number of subjects: 97
Study: 9131646

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8074963

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 3446275

Group type: EXPERIMENTAL
Intervention: Practolol at 200 mg bd
Number of subjects: 3052

Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 3052

Group type: EXPERIMENTAL
Intervention: Pre-trial non-smokers (NS)
Number of subjects: 3052
Study: 29540274

Group type: EXPERIMENTAL
Intervention: Quercetin (1 g/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 26717881

Group type: EXPERIMENTAL
Intervention: Nicotine (0.1, 0.2, 0.3, or 0.4 mg doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study: 25847577

Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health Jr. (HH) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health Jr. Obesity Prevention Effectiveness Trial (HH Effectiveness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) study
Number of subjects: 0
Study: 23095194

Group type: EXPERIMENTAL
Intervention: Leakection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Amnioquick
Number of subjects: 200
Study: 20943209

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM
Number of subjects: 2907

Group type: COMPARATOR
Intervention: MCV4
Number of subjects: 2907

Group type: COMPARATOR
Intervention: MenACWY‐CRM and MCV4
Number of subjects: 2907
Study: 18580398

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) - Lo/Ovral (30 microg of ethinyl estradiol and 0.3 mg of norgestrel)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 16776446

Group type: COMPARATOR
Intervention: Isoniazid (INH) 300 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1000 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (moxifloxacin, gatifloxacin, levofloxacin)
Number of subjects: 40
Study: 14653287

Group type: EXPERIMENTAL
Intervention: Conditioned with 20% polyacrylic acid for 10 seconds
Number of subjects: 42

Group type: COMPARATOR
Intervention: No surface treatment (control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Etched with 37% phosphoric acid for 15 seconds
Number of subjects: 42
Study: 10334255

Group type: EXPERIMENTAL
Intervention: Combination therapy (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Single drug therapy (sulphasalazine, with or without methotrexate and prednisolone)
Number of subjects: 199
Study: 8944991

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF) with a polysulfone ultrafiltrator before extracorporeal circulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 17
Study: 1673592

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.04 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.07 mg/kg
Number of subjects: 20
Study: 7081646

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Trichloroethylene
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lumbar extradural anaesthesia
Number of subjects: 36
Study: 29773176

Group type: EXPERIMENTAL
Intervention: Zinc, magnesium, and chromium supplementation (300 mg magnesium, 600 μg chromium, 36 mg zinc per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26854810

Group type: EXPERIMENTAL
Intervention: Maraviroc 150mg once daily with darunavir/ritonavir
Number of subjects: 797

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine once daily with darunavir/ritonavir
Number of subjects: 797
Study: 24371012

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study: 22743661

Group type: EXPERIMENTAL
Intervention: CBIT delivered over videoconference
Number of subjects: 20

Group type: COMPARATOR
Intervention: CBIT via traditional face-to-face delivery
Number of subjects: 20
Study: 20433042

Group type: EXPERIMENTAL
Intervention: BT/ER curriculum participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants completing at least 45 hours of training in the past year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who did not report significant amounts of training
Number of subjects: 0
Study: 18768506

Group type: EXPERIMENTAL
Intervention: Presence of one or more sexually transmissible infections (STIs)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: IgA antibody to Chlamydia trachomatis
Number of subjects: 868

Group type: COMPARATOR
Intervention: Individual STIs (Chlamydia trachomatis, HPV-16 and -18, herpes simplex virus-2, cytomegalovirus, human herpesvirus-8)
Number of subjects: 868
Study: 15857076

Group type: EXPERIMENTAL
Intervention: Test Tooth (TT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Contralateral Tooth (CT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Antagonist Tooth (AT)
Number of subjects: 17
Study: 12423714

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10412786

Group type: EXPERIMENTAL
Intervention: Prednisone and azathioprine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prednisone and cyclosporine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prednisone, azathioprine, and cyclosporine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Healthy, age‐ and sex‐matched subjects
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prednisone (dose-dependent)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall immunosuppressive therapy
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: LDL triglyceride/apo B ratio
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Total serum cholesterol
Number of subjects: 216
Study: 7567321

Group type: EXPERIMENTAL
Intervention: Extended intervention (hospital packet + oral and written advice at 2 weeks, 2, 4, and 6 months)
Number of subjects: 2901

Group type: COMPARATOR
Intervention: Minimal intervention (hospital packet only)
Number of subjects: 2901
Study: 2145235

Group type: EXPERIMENTAL
Intervention: enoximone, 150 mg t.d.s.
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 7387340

Group type: EXPERIMENTAL
Intervention: 20 mg of haloperidol on day 1, increasing increments of 20 mg daily, maximum 100 mg daily on day 5
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 10 mg of haloperidol on day 1, increasing increments of 10 mg daily, maximum 100 mg daily on day 10
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fixed dosage of 10 mg daily for ten days
Number of subjects: 63
Study: 6133525

Group type: EXPERIMENTAL
Intervention: Astemizole (single administration)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Ketotifen (reference substance)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Astemizole (seven days of treatment)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (seven days of treatment)
Number of subjects: 85
Study: 30959123

Group type: EXPERIMENTAL
Intervention: Post-neoAS, pre-RT PSA level >0.1 ng/mL
Number of subjects: 2404
Study: 30148430

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (PAAG), 3 ml, up to two injections 1 month apart.
Number of subjects: 84
Study: 26916483

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9236

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9236

Group type: EXPERIMENTAL
Intervention: CYP2C19 metabolizer status
Number of subjects: 9236
Study: 24968790

Group type: EXPERIMENTAL
Intervention: HS219 (40 mg chitosan‐loaded chewing gum)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HS219
Number of subjects: 68
Study: 22490690

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (LR)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional open resection (OR)
Number of subjects: 108
Study: 20703158

Group type: EXPERIMENTAL
Intervention: Maraviroc once daily
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Maraviroc twice daily
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1049
Study: 18827119

Group type: EXPERIMENTAL
Intervention: 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 regimen
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study: 16054802

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone (4-12 mg/day)
Number of subjects: 0
Study: 11807486

Group type: EXPERIMENTAL
Intervention: Mandibular implant-supported overdentures (IOD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional mandibular dentures (CD)
Number of subjects: 68
Study: 10987630

Group type: EXPERIMENTAL
Intervention: Self-help booklet tailored to smoking patterns, stage of change, and lifestyle of pregnant smokers
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Self-help booklet plus access to a computerized telephone cessation program based on interactive voice response technology
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Self-help booklet plus proactive telephone counseling from nurse educators using motivational interviewing techniques and strategies
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (usual care advice from prenatal providers)
Number of subjects: 390
Study: 7726807

Group type: EXPERIMENTAL
Intervention: Arousal training (combining the alarm device with reinforcement for correct behaviour)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control conditions (other means without alarm device)
Number of subjects: 113
Study: 2150025

Group type: EXPERIMENTAL
Intervention: legume-supplemented normal caloric diet for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: usual diet
Number of subjects: 40
Study: 7310594

Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no caffeine treatment)
Number of subjects: 18
Study: 31757470

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: TMI
Number of subjects: 432
Study: 31181973

Group type: EXPERIMENTAL
Intervention: First-line pembrolizumab monotherapy
Number of subjects: 386

Group type: COMPARATOR
Intervention: KEYNOTE-024 (KN024)
Number of subjects: 386

Group type: COMPARATOR
Intervention: KEYNOTE-042 (KN042)
Number of subjects: 386
Study: 29191325

Group type: EXPERIMENTAL
Intervention: PFO closure with the Amplatzer PFO Occluder device
Number of subjects: 230

Group type: COMPARATOR
Intervention: Medical therapy with a sham procedure (right heart catheterization)
Number of subjects: 230
Study: 25526831

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 sessions
Number of subjects: 33

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 33
Study: 24180003

Group type: EXPERIMENTAL
Intervention: MAALES intervention
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control group (single, individualized HIV risk-reduction session)
Number of subjects: 437
Study: 22011688

Group type: EXPERIMENTAL
Intervention: Flupirtine (100 - 400 mg/d)
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Active comparators
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 1046
Study: 18696272

Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (mRS) scores
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Barthel Index (BI) scores
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale (NIHSS) scores
Number of subjects: 820
Study: 16965740

Group type: EXPERIMENTAL
Intervention: Fuzheng Kang'ai Granules combined with super-selective intra-arterial chemotherapy (EAP regime: VP(16) 100 mg/m(2) + epirubicin 60 mg/m(2) + carboplatin 200 mg/m(2))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (super-selective intra-arterial chemotherapy only)
Number of subjects: 40
Study: 12942015

Group type: EXPERIMENTAL
Intervention: Distress Risk Assessment Method
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Roland Morris Disability Questionnaire
Number of subjects: 221
Study: 10896068

Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 132
Study: 9290168

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) treatment for 3 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (age-matched healthy volunteers)
Number of subjects: 13
Study: 8497820

Group type: EXPERIMENTAL
Intervention: Theophylline treatment at a steady state plasma concentration of 17 mg/l
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Theophylline treatment at a steady state plasma concentration of 10 mg/l
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 15
Study: 3126683

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation (group A)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normoventilation (group B)
Number of subjects: 102
Study: 29520080

Group type: EXPERIMENTAL
Intervention: CYP2C19 loss-of-function (LOF) carriers
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 1476
Study: 28570163

Group type: EXPERIMENTAL
Intervention: Direct-access online care
Number of subjects: 156

Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 156
Study: 24704421

Group type: EXPERIMENTAL
Intervention: Light-intensity walking
Number of subjects: 10

Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standing every 20 min
Number of subjects: 10
Study: 23076837

Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program, which consists of mentoring and skills groups
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program
Number of subjects: 156
Study: 21418055

Group type: EXPERIMENTAL
Intervention: computer‐assessed reading intervention (n=25)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: regular remedial reading intervention (n=25)
Number of subjects: 166

Group type: COMPARATOR
Intervention: mainstream reading instruction (n=116)
Number of subjects: 166
Study: 18790817

Group type: EXPERIMENTAL
Intervention: Red wine (240 ml/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vodka (80 ml/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Both interventions (Red wine and Vodka)
Number of subjects: 78
Study: 16567032

Group type: EXPERIMENTAL
Intervention: Polymer crowns with glass-fiber framework
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Polymer crowns without fiber reinforcement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metal-ceramic crowns
Number of subjects: 120
Study: 12589387

Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11074805

Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine (Sjögren subgroup)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporine
Number of subjects: 32
Study: 8826949

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 41802

Group type: EXPERIMENTAL
Intervention: Early detection of prostate carcinoma via PSA screening
Number of subjects: 41802
Study: 1576060

Group type: EXPERIMENTAL
Intervention: Histamine inhalation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Inhaled saline (placebo)
Number of subjects: 15
Study: 3930437

Group type: EXPERIMENTAL
Intervention: Home-baked gliadin-containing gluten-free bread, 6 slices daily for 6 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control period (not specified)
Number of subjects: 10
Study: 31399454

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - 8 weeks, twice a day, 5 days a week, with weekly physiotherapist visits; unsupervised IMT twice a day three times a week until follow-up at 6 months.
Number of subjects: 11
Study: 29294598

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + methotrexate (MTX)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo + methotrexate (MTX)
Number of subjects: 127
Study: 27791228

Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment (MNA)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Malnourished patients (assessed by MNA)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Patients at risk for malnutrition (assessed by MNA)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Well-nourished patients (assessed by MNA)
Number of subjects: 226
Study: 24372085

Group type: EXPERIMENTAL
Intervention: PC-tablet based intervention providing tailored information about breast cancer risk
Number of subjects: 1261
Study: 22469449

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg twice daily
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg once daily
Number of subjects: 728
Study: 21446627

Group type: EXPERIMENTAL
Intervention: 12-hour drain clamping
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous drainage
Number of subjects: 50
Study: 18852401

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 458
Study: 16102631

Group type: EXPERIMENTAL
Intervention: Prostaglandin E‐1 (PGE‐1) infusion for 20 days
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo infusion for 20 days
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Prostaglandin E‐1 (PGE‐1) infusion
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 87
Study: 12420730

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous metronidazole 500 mg preoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multi-drug regimen (intravenous cefuroxime 1.5 g and metronidazole 0.5 g preoperatively, and oral co-amoxiclav 375 mg 8-hourly postoperatively)
Number of subjects: 50
Study: 10626589

Group type: EXPERIMENTAL
Intervention: Congenital hypothyroidism (CH) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (siblings, classmates, and matched controls for age and gender)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CH group
Number of subjects: 100
Study: 7719242

Group type: EXPERIMENTAL
Intervention: VBMCP (Vincristine, BCNU, melphalan, cyclophosphamide, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VBMCP alternating with interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: VBMCP with intermittent high dose cyclophosphamide
Number of subjects: 0